More effective chemotherapy sequence in breast cancer identified

Share this content:

Administering paclitaxel before anthracyclines leads to better relapse-free survival rates for patients with breast cancer than does using the drugs in the reverse order.

A retrospective analysis of 1,414 patients with breast cancer (stages I – III) who underwent primary systemic therapy and 1,596 on adjuvant chemotherapy

evaluated the clinical outcomes of the two different sequences of paclitaxel and anthracyclines over a 15-year period. Both cohorts were balanced by hormone-receptor status, clinical stage, and menopausal status.

The analysis revealed that anthracyclines-before-paclitaxel yielded inferior outcomes. In primary systemic therapy, this combination was associated with a significantly higher risk of relapse, but not death. In the adjuvant-chemotherapy group, anthracyclines-before-paclitaxel was significantly associated with a higher risk of death, but not relapse.

The 5-year relapse-free survival rate for those receiving paclitaxel before anthracyclines as primary systemic therapy was 79%, compared with 61.2% when the reverse order was used. The 5-year overall survival rate was 84.2% when paclitaxel was used first in primary systemic therapy, compared with 71.3% when the regimen started with anthracyclines.

When used as adjuvant chemotherapy, paclitaxel-first was associated with a 5-year relapse-free survival rate of 88.8% and a 5-year overall survival rate of 93.1%. When anthracyclines preceded paclitaxel, those rates fell to 79.5% and 83.2%, respectively.

“This retrospective analysis is hypothesis-generating and should lead to a prospective randomized trial to compare the two sequences as [primary systemic therapy] and [adjuvant chemotherapy] in locally advanced or early [breast cancer], respectively,” wrote Ricardo Hugo Alvarez, MD, of the M. D. Anderson Cancer Center (Houston, Texas), and fellow investigators in an abstract presented at the recent San Antonio Breast Cancer Symposium (

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs